Table 2.
RA Patient demographic and clinical characteristics.
| Total | Men | Women | |
|---|---|---|---|
| COMPLETE BLOOD COUNT | |||
| Leukocytes (mil/mL) | 6.7 ± 2.4 | 9.27 ± 1.6 | 6.41 ± 2.28 (**) |
| Hemoglobin (g/L) | 124.5 ± 14.31 | 136.5 ± 10.9 | 123.07 ± 13.84 (*) |
| Erythrocytes (mil/μL) | 4.45 ± 0.47 | 4.77 ± 0.29 | 4.41 ± 0.47 (*) |
| Platelets (mil/mL) | 292.5 ± 85.31 | 307.3 ± 96.48 | 290.76 ± 82.86 |
| Basophils (mil/mL) | 0.04 ± 0.024 | 0.05 ± 0.02 | 0.037 ± 0.03 |
| Lymphocytes (mil/mL) | 1.79 ± 0.69 | 2.22 ± 0.45 | 1.74 ± 0.68 |
| Monocytes (mil/mL) | 0.54 ± 0.23 | 0.85 ± 0.25 | 0.5 ± 0.19 (*) |
| Neutrophils (mil/mL) | 4.1 ± 1.9 | 5.8 ± 1.18 | 3.91 ± 1.87 (*) |
| Eosinophils (mil/mL) | 0.15 ± 0.19 | 0.46 ± 0.38 | 0.11 ± 0.09 |
| BLOOD ASSAYS | |||
| ESR (mm/h) | 20.6 ± 12.47 | 18.83 ± 12.02 | 20.8 ± 12.38 |
| CRP (mg/L) | 14.72 ± 17.45 | 29.81 ± 19.07 | 12.94 ± 16.17 |
| RF (U/ml) | 62.88 ± 66.11 | 62.54 ± 50.19 | 62.91 ± 67.09 |
| ACPA (U/ml) | 135.6 ± 212.3 | 114.82 ± 118.5 | 138.01 ± 218.6 |
| CTHRC1, ng/ml | 20.39 ± 25.38 | 33.36 ± 31.72 | 18.86 ± 23.8 |
| CLINIC | |||
| N | 57 | 6 | 51 |
| Age | 49.51 ± 13.65 | 47.83 ± 15.62 | 49.71 ± 13.24 |
| DAS28-CRP | 3.78 ± 0.85 | 3.94 ± 0.58 | 3.76 ± 0.87 |
| Age of onset (years) | 42.0 ± 14.58 | 36.66 ± 13.8 | 42.63 ± 14.54 |
| Duration of disease (years) | 8.04 ± 8.18 | 11.5 ± 10.07 | 7.67 ± 7.8 |
| Duration of treatment (years) | 5.05 ± 6.27 | 8.76 ± 9.39 | 4.41 ± 5.3 |
| Tender joint count (0-28) | 8.12 ± 3.07 | 8.16 ± 3.28 | 8.10 ± 3.04 |
| Swollen joint count (0-28) | 2.12 ± 2.27 | 1.16 ± 0.68 | 2.24 ± 2.38 (*) |
| TREATMENT | |||
| Mtx | 54.25% | n.a. | n.a. |
| MTX + GC | 17.5% | n.a | n.a |
| Mtx + DMARDs | 5.25% | n.a. | n.a. |
| Mtx + NSAIDs | 1.75% | n.a | n.a |
| GC | 3.5% | n.a. | n.a. |
| DMARDs | 3.5% | n.a | n.a |
| Mtx+ | 3.5% | n.a. | n.a. |
| SSZ | 1.75% | n.a | n.a |
| None | 9.0% | n.a | n.a |
*p-values for statistical difference between men and women parameters were calculated using Mann–Whitney U-test:
p < 0.05;
p < 0.01.
Average values with standard deviation (±SD) are presented. n.a. —parameter not determined. ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; DAS28-CRP, disease activity score based on CRP. Mtx, methotrexate or metoject; Mtx + GC, methotrexate in combination with glucocorticoids; Mtx + DMARDs, methotrexate in combination with other synthetic DMARDs (leflunomide or hydroxychloroquine); Mtx + NSAIDs, methotrexate in combination with non-steroidal anti-inflammatory drugs; Mtx +, methotrexate in combination with NSAIDs and synthetic DMARDs, with or without ibandronate; GC, glucocorticoids (prednisolone or methylprednisolone); DMARDs, leflunomide or hydroxychloroquine alone or in combination; SSZ, sulfasalazine.